Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer

16 listopada 2026 zaktualizowane przez: Lee, Soo Hyeon, Korea University Anam Hospital

A Phase 2, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Erlotinib in Patients With EGFR-Amplified Metastatic Colorectal Cancer Who Have Failed or Are Not Eligible for Oxaliplatin- and Irinotecan-Based Chemotherapy

This phase II, open-label, single-arm clinical trial is designed to evaluate the efficacy and safety of a combination therapy with bevacizumab and erlotinib as a salvage treatment in patients with metastatic colorectal cancer who have failed or are intolerant to standard oxaliplatin- and irinotecan-based chemotherapy, and whose tumors harbor an EGFR copy number gain of 4 or higher confirmed by NGS testing. The primary objective is to evaluate progression-free survival (PFS), and secondary objectives include objective response rate (ORR), overall survival (OS), disease control rate (DCR), safety, and quality of life.

Przegląd badań

Szczegółowy opis

This study investigates the clinical benefit of combining an anti-VEGF agent (bevacizumab) with an EGFR tyrosine kinase inhibitor (erlotinib) in refractory metastatic colorectal cancer with EGFR amplification. Eligible patients will receive bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral erlotinib at 150 mg. Tumor assessments will be conducted periodically using RECIST version 1.1 to determine clinical outcomes, and toxicities will be graded according to NCI CTCAE version 5.0.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

39

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

19 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Histologically or cytologically proven metastatic/recurrent colorectal cancer who have failed or are intolerant to standard chemotherapy based on oxaliplatin and irinotecan (and if RAS wild-type, an anti-EGFR therapy).

  2. EGFR copy number gain ≥ 4 confirmed by NGS testing performed at the participating institution.

  3. Measurable disease per RECIST version 1.1 (measurable lesions are not mandatory for study entry).

  4. Age ≥ 19 years.

  5. ECOG performance status 0-2.

  6. Adequate bone marrow and organ function:

    • Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
    • Hemoglobin (Hgb) ≥ 9.0 g/dL
    • Platelet count ≥ 75 x 10^9/L
    • Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 30 mL/min
    • Total bilirubin ≤ 2.0 x ULN (subjects with biliary obstruction are eligible if criteria are met after appropriate biliary drainage)
    • AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
  7. Adequate cardiac function: QTc ≤ 480 msec (if QTc > 480 msec, average QTc < 480 msec in triplicate measurements).

  8. Ability to swallow oral medication.

  9. Negative serum β-HCG pregnancy test within 14 days prior to study drug administration for female patients of childbearing potential.

  10. Agreement to use appropriate contraception methods as outlined in the protocol.

  11. Life expectancy ≥ 3 months.

  12. Signed and dated informed consent prior to any study-related procedures.

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Prior history of combination therapy with an EGFR tyrosine kinase inhibitor and anti-VEGF blockade.
  3. Known hypersensitivity to the study drug components.
  4. Cytotoxic chemotherapy within 14 days, investigational drugs within 2 weeks or 5 half-lives, or monoclonal antibody therapy within 4 weeks prior to study entry.
  5. Uncontrolled severe infection.
  6. Severe medical or psychiatric conditions including active cardiac disease, uncontrolled hypertension, significant arrhythmias, or conditions prolonging QTc.
  7. Active central nervous system (CNS) metastases (unless radiologically stable, asymptomatic, and off steroids for at least 4 weeks; leptomeningeal disease is excluded).
  8. History of another primary malignancy (except adequately treated non-melanoma skin cancer, superficial cervical carcinoma, stage 1 bladder cancer, completely resected thyroid cancer, or other solid tumors with no evidence of recurrence for at least 36 months).
  9. Persistence of toxicities from prior anticancer therapy > Grade 1 (except alopecia).
  10. Extensive radiotherapy to the bone marrow within 4 weeks or limited radiotherapy within 2 weeks prior to study entry.
  11. Major surgery within 4 weeks prior to study entry or unrecovered from surgical side effects.
  12. Thrombotic or thromboembolic events within 6 months.
  13. History or evidence of bleeding disorders.
  14. Therapeutic use of maximum dose anticoagulants.
  15. Unhealed wounds, acute ulcers, or bone fractures.
  16. Abdominal fistula, gastrointestinal perforation, or active GI bleeding within 6 months.
  17. Urine dipstick protein ≥ 2+ with 24-hour urine protein > 1g.
  18. History or pathological findings of major GI surgery that may impair oral absorption.
  19. Evidence of active infection including Hepatitis B, Hepatitis C, or HIV (subjects with controlled or inactive HBV/HCV under specific protocol criteria are permitted).
  20. Conditions or diseases deemed by the investigator to contraindicate study participation.
  21. Medical, psychological, cognitive, or other conditions that impair the subject's ability to understand, consent, or comply with protocol procedures.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Bevacizumab plus Erlotinib

Participants will receive Bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral Erlotinib at 150 mg.

Administered at 7.5 mg/kg intravenously every 3 weeks.

Inne nazwy:
  • Onbevzi

Administered at 150 mg orally daily.

Inne nazwy:
  • Eltinib

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Progression-Free Survival (PFS)
Ramy czasowe: From the first dose of study treatment until disease progression or death, assessed up to 12 months

PFS is calculated from the date of the first administration of the study drug to the date of documented disease progression or death from any cause.

From the first dose of study treatment until disease progression or death, assessed up to 12 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Objective Response Rate (ORR)
Ramy czasowe: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) evaluated using RECIST version 1.1.

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Overall Survival (OS)
Ramy czasowe: From the first dose of study treatment until death, assessed up to 1 year of survival follow-up

OS is calculated from the date of the first administration of the study drug to the date of death from any cause or the last follow-up date

From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
Disease Control Rate (DCR)
Ramy czasowe: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve CR, PR, or stable disease (SD) maintained for at least 6 weeks after study drug administration

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Duration of Response (DOR)
Ramy czasowe: From initial response until documented disease progression, assessed up to approximately 12 months

Calculated from the time initial response (CR or PR) is documented until the date of progressive disease

From initial response until documented disease progression, assessed up to approximately 12 months
Time to Response (TTR)
Ramy czasowe: From the first dose of study treatment until the first documented response, assessed up to approximately 12 months

Calculated from the first dose of study treatment to the date of initial response (CR or PR)

From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
Safety and Tolerability
Ramy czasowe: From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months

Evaluated by type, frequency, and severity of adverse events graded according to NCI CTCAE version 5.0

From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
Quality of Life (QoL) EORTC QLQ-C30
Ramy czasowe: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
Quality of Life (QoL) CR26
Ramy czasowe: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (CR26)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

4 stycznia 2027

Zakończenie podstawowe (Szacowany)

31 stycznia 2028

Ukończenie studiów (Szacowany)

31 stycznia 2030

Daty rejestracji na studia

Pierwszy przesłany

10 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

16 listopada 2026

Pierwszy wysłany (Rzeczywisty)

17 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

16 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Yes. De-identified individual participant data underlying the results reported in this article, after de-identification, will be shared beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. Data getters will be required to sign a data access agreement.

Ramy czasowe udostępniania IPD

Beginning 3 months and ending 5 years following article publication.

Kryteria dostępu do udostępniania IPD

De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to the corresponding author. Data requesters will be required to sign a data access agreement.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj